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Summary The possibility of renal damage by hydroxy-
ethyl starch has become the focus of intensive dispute 
based on the findings of published large trials. The aim 
of this narrative review is to analyze outcome reporting 
bias in the literature on volume resuscitation, focusing 
on selective outcome reporting in published randomized 
and observational trials with “modern” hydroxyethyl 
starch as therapeutic intervention. Three recent publi-
cations claimed to confirm renal safety of hydroxyethyl 
starch 130/0.4 for indications in severe sepsis, trauma, 
and critical illness, respectively. Selective outcome 
reporting was identified in these studies including under-
reporting of side effects and change of primary study out-
comes. In conclusion, selective outcome reporting bias is 
identified in recent publications of clinical trials on vol-
ume resuscitation with HES.
Keywords Hydroxyethyl starch · Renal injury · Reporting 
bias
Publikationsbias in klinischen Studien zur 
Volumentherapie mit Hydroxyethylstärke
Zusammenfassung Die Gefahr der Nierenschädigung 
durch Hydroxyethylstärke (HES) hat sich zu einem 
Hauptthema der Diskussion von Ergebnissen rezenter 
klinischer Studien entwickelt. Ziel dieses Kommentars 
ist es, Vorhandensein und Art von Publikationsbias in 
der klinischen Forschung mit Hydroxyethylstärke zu 
analysieren, wobei der Schwerpunkt auf der selektiven 
Berichterstattung von Ergebnissen in randomisierten 
kontrollierten Untersuchungen und Beobachtungsstu-
dien mit „moderner“ Hydroxyethylstärke liegt. Drei aktu-
elle Publikationen postulierten renale Sicherheit von 
Hydroxyethylstärke 130/0,4 in den Indikationen schwere 
Sepsis, Trauma und intensivstationspflichtige Krankheit. 
Selektive Ergebnisberichterstattung wurde in allen drei 
Studien identifiziert einschließlich der Unterschlagung 
von Nebenwirkungen und der Abänderung von vorde-
finierten primären Studienendpunkten. Publikations-
bias in Form selektiver Berichterstattung in mehreren 
jüngsten Veröffentlichungen klinischer Prüfungen zur 
Volumentherapie mit HES erschwert die Arbeit von Arz-
neimittelbehörden, pharmazeutischem und ärztlichem 
Personal.
Schlüsselwörter Hydroxäthylstärke 130/0,40–0,42 · Aku te 
Nierenschädigung · Publikationsbias
Introduction
Reporting bias is of two types, including, at the study 
level, absence of a publication because of failure to sub-
mit to, or rejection by, scientific journals, and the selec-
tive non-reporting of outcomes at the outcome level [1]. 
On average about half of all clinical studies are fully pub-
lished [2–6]. This means that only part of the available 
evidence on a topic is being made public. Furthermore, 
in various reviews extensive selective reporting in study 
publications has been found [7–9] including introduc-
tion, omission, or change of primary study outcomes [7, 
9]. Reporting bias particularly concerns adverse events 
that are not reported [10–13].
In the fields of perioperative, emergency, and critical 
care medicine, hydroxyethyl starch (HES) solutions are 
commonly used for volume resuscitation. In March 2011, 
88 publications of Dr. J. Boldt, at one time a prolific Ger-
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man anesthesiologist and pre-eminent authority on the 
perioperative use of HES, were retracted because he 
allegedly failed to secure approval from an institutional 
review board for his studies [14]. In addition, several of 
his papers were determined to have been fabricated [15]. 
New meta-analyses assessing outcomes after HES expo-
sure demonstrated no overall effect of HES on survival. 
However, after exclusion of seven sepsis and trauma stud-
ies by Dr. Boldt’s group, significantly increased mortality 
was shown among HES recipients [16]. Despite existing 
concerns about the drug’s safety, in particular a neph-
rotoxic potential that is held responsible for the require-
ment of renal replacement therapy (RRT) in a significant 
number of patients receiving HES [17], lack of an asso-
ciation with acute kidney injury continues to be claimed 
for certain clinical conditions and doses of HES [18]. The 
arguments in favor of this claim are based on trial data 
that were published more recently [19–21]. These publi-
cations are analyzed here in a narrative review that iden-
tifies various types of significant reporting bias.
Hydroxethyl starch for volume resuscitation
Clinical use
In the past 15 years, colloids have been increasingly 
widely used for volume resuscitation in patients with 
severe acute disease [22]. In Europe, volume resuscita-
tion was achieved preferentially with HES, an artificial 
colloid derived from plant starch. One of the reasons for 
the increasing use of HES, despite safety concerns, is that 
under physiological conditions iso-oncotic HES infusion 
solutions are more effective volume expanders than iso-
tonic crystalloid solutions such as 0.9 % sodium chloride 
[23], and furthermore that artificial colloids like HES are 
associated with a lower cost than the natural colloid albu-
min [24]. The widespread use of HES has been accompa-
nied by an increase in safety concerns, particularly with 
respect to kidney damage, bleeding, and severe, persis-
tent, delayed-onset pruritus [25–29]. The risk of these 
complications became known soon after the introduc-
tion of HES as a volume replacement therapy (reviewed 
in [25]). Marketing authorization for HES was obtained 
in the late 1960s without the rigorous evaluation of effec-
tiveness and safety in large phase III trials that would be 
required today. However, as early as 1968 a fall in plate-
let count and clinical bleeding was reported in a study of 
HES-treated patients [30]; later, in 1992, a warning about 
HES and kidney failure was published [31].
Initial strategies to reduce the known risks of HES 
included redefining the maximum daily dose for differ-
ent HES preparations [32] and attempting to optimize 
the crude material used in the manufacture of HES. The 
resulting changes in pharmacodynamics and pharma-
cokinetics were expected to improve the tolerability of 
the substance. Development of lower molecular weight 
products and alteration of the degree of hydroxyethyl 
substitution led to “new generation” HES which became 
part of the marketing strategy by the HES producing 
companies [33]. “Molar substitution”, the proportion of 
the glucose rings with at least one hydroxyethyl group, is 
another feature of HES products; for example, at a sub-
stitution of 0.5, 50 % of the glucose rings are substituted 
with at least one hydroxyethyl group. The original “first 
generation” HES had a molecular weight (MW) of about 
450,000 with a rate of molar substitution of 0.7. The sec-
ond generation HES had a MW of 200,000 with a substi-
tution of 0.62 or 0.5, and the third generation now has a 
MW of 130,000 with a substitution of only 0.4. Third gen-
eration HES 130/0.4 and 130/0.42 in clinical use is pro-
duced from corn starch and potato starch, respectively. 
For infusion, HES is dissolved in 0.9 % saline or balanced 
electrolyte solution where part of the chloride is replaced 
with lactate or acetate.
Safety concerns regarding “modern” hydroxyethyl 
starch
First serious doubts about the tolerability of “modern” 
(second and third) generation HES arose from studies 
in the intensive care unit (ICU) [34, 35]. In these stud-
ies in critically ill patients with severe sepsis, HES with a 
MW of 200,000 was compared either with gelatin [34] or 
crystalloid solution [35]. Administration of HES in septic 
patients was associated with adverse effects on the kid-
neys that were observed within a follow-up period of 90 
days, with the effects being dose-dependent (with high 
doses of HES there was a trend for a higher rate of death) 
[35]. The applicability of these results to third generation 
HES has been strongly challenged. The hypothesis that 
third generation HES is safer than previous generations 
of HES, however, was not based on valid data [24, 36]. 
In 2012, two blinded, randomized, controlled studies, 
the 6S [37] and the Crystalloid vs. Hydroxyethyl Starch 
Trial (CHEST) [38] studies were published. Both studies 
included large numbers of patients, steadily decreasing 
HES dosages, and follow-up periods sufficiently long (90 
days) to observe delayed side effects. In the two studies, 
potato [37] and corn starch-based [38] third generation 
HES solutions were evaluated at doses significantly lower 
than those authorized according to the manufacturers 
(50  ml/kg body weight/day). After 90 days of follow-
up in the 6S study, patients with severe sepsis receiv-
ing HES required RRT more often than those receiving 
Ringer’s acetate solution. There was also an increased 
incidence of end-stage renal failure and a higher mor-
tality rate, and the median cumulative dose of HES was 
44 ml/kg of ideal body weight [37]. In the CHEST study, 
where most postoperative patients had been admitted 
without sepsis, there was an increased rate of RRT in the 
HES than in the normal saline group. In addition, during 
the first 7 days after admission to the study, the serum 
creatinine concentrations were significantly higher, and 
the excreted urine volumes significantly lower, than 
in the normal saline group. In the CHEST study, which 
included patients with markedly lower disease severity 
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strate a difference in the incidence of renal failure. In the 
HES group, 24 of 98 patients (24.5 %) developed renal 
failure compared with 19 of 95 (20 %) in the saline group. 
After 90 days, 21 patients in the HES group required RRT, 
almost twice as many as in the saline group (n = 11). 
These study data were not reported in the journal article 
but have been added to the Voluven Package Insert by 
FDA [49, 50].
Case 2
In the randomized, double-blind Fluid-in-Resusci-
tation-of-Severe-Trauma (FIRST) study, 0.9 % saline 
was prospectively compared with HES 130/0.4 for ini-
tial volume resuscitation in 67 patients with penetrat-
ing trauma and 42 patients with blunt trauma [20]. In 
patients with penetrating trauma, significantly less vol-
ume was needed for resuscitation in the colloid group 
compared with the crystalloid group, and the incidence 
of renal failure was significantly lower. The FIRST trial 
included an observation period of 30 days but lacked the 
power to address renal safety. In the published report, 
improvement in renal function in patients with pen-
etrating trauma receiving HES 130/0.4 was emphasized. 
In contrast, an observed increase in transfusion of blood 
products in HES 130/0.4 recipients with blunt trauma 
was minimized [51].
In the trial register entry (ISRCTN42061860), pre-
specified endpoints included two primary and seven 
secondary endpoints [52]. However, in the published 
report, three safety endpoints were described that were 
not included in the original protocol; one of these was 
acute kidney injury [51]. Thus, there is considerable dis-
crepancy between the prespecified study endpoints and 
those in the published report.
The CONSORT authors recommend that effect size 
and confidence interval are given for each primary and 
secondary outcome [53]. James et al. [20] have not done 
this but concluded that HES improved renal function. 
However, serious concerns have been raised on how 
such a conclusion could have been made, as additional 
information would have been required, which was not 
presented in the publication [54].
Case 3
The retrospective study of Boussekey et al. [19] included 
363 patients hospitalized for more than 72 h in the ICU. 
Of these, 168 patients received HES during their stay and 
195 did not [19]. The authors concluded that HES did not 
induce acute kidney injury because patients in the HES 
group were more severely ill on admission; however, 
acute kidney injury incidence and ICU mortality was 
similar in both groups [19]. This publication has been 
used to provide evidence that low doses of HES 130/0.4 
do not cause kidney failure and cited in the recent 
meta-analysis on the effects of waxy maize-derived HES 
than the 6S study, mortality was not significantly affected 
by HES; the median daily dose of HES was 8  ml/kg of 
body weight [38].
After the publication of these large randomized and 
blinded studies, meta-analyses confirmed that HES solu-
tions, including third generation HES, exerted negative 
effects on renal and hepatic function, and coagulation 
[16, 17, 39–43]. It was concluded that HES should no lon-
ger be used in the ICU or in critically ill patients.
On June 14, 2013 in its risk assessment process, the 
Pharmacovigilance and Risk Assessment Committee 
(PRAC) of the European Medicines Agency (EMA) con-
cluded that the benefits of HES no longer outweigh the 
risks and recommended the suspension of all HES mar-
keting authorizations [44]. In the United States of Amer-
ica, the Food and Drug Administration (FDA) issued a 
“boxed warning” [45].
Fraudulent Hydroxyethyl starch research affecting 
the controversy about the clinical use of 
hydroxyethyl starch
Among opinion leaders and physicians, very different 
perceptions and treatment algorithms are proposed 
for volume resuscitation with crystalloids and colloids, 
inspite of the evolving evidence base described above. 
The opinions presented are controversial [46]. Accord-
ing to many, successful commercialization by the manu-
facturers rather than scientific evidence lies behind the 
widespread use of HES [47]. Furthermore, the contro-
versy is apparently affected by the “Boldt case”, a particu-
larly impressive example of scientific misconduct [14].
Reporting bias in hydroxyethyl starch clinical 
research publications
Case 1
Volume resuscitation with HES is still proposed by some 
clinicians [48] for various clinical scenarios, including 
the initial phase of sepsis, despite evidence of safety con-
cerns. This view appears to be based on the CRYSTMAS 
trial [21], a double blind, prospective, randomized study 
of 174 septic patients, in whom no significant between-
group differences were described following an observa-
tion period of 90 days. The trial compared the use of 6 % 
HES 130/0.4 and 0.9 % saline in severe sepsis to fulfill a 
postmarketing study commitment issued by the US FDA. 
Trial outcomes, however, were selectively published 
[49]. When the more complete data set presented to FDA 
was evaluated, the results suggested that the use of HES 
130/0.4 did not lead to clinically relevant volume savings 
(the primary outcome parameter), that there were nega-
tive effects on kidney function similar to those observed 
with an older HES solution, and also that there was a 
6.8 % increase in 90-day mortality [50]. An obvious limi-
tation of the study was that it was too small to demon-
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et al. [19] provides evidence of potential deleterious renal 
effects associated with starch infusion [57, 58].
Discussion
Reporting bias is a problem in volume resuscitation 
research. The increased likelihood for a study of being 
published when results are positive or favorable results 
is well known than when negative or unfavorable results 
were observed [7]. Within a study, selective reporting 
involves analyses or outcomes [1]. In the three publica-
tions discussed here [19–21], reporting bias consisted 
of selective underreporting of side potential effects [19, 
21, 49, 50, 57, 58], selective reporting of analyses [21, 57, 
58], and presentation of safety endpoints that were not 
predefined in the study protocol [20, 51, 53]. In the con-
text of the ongoing debate on the use of HES for volume 
resuscitation at both clinical and regulatory levels, it is 
important to make reporting bias public if studies are 
being used as evidence base regulatory decision making 
[44, 45, 48, 56].
Industry sponsorship or industry affiliation of 
authors is associated with positive research outcomes 
and conclusions [59]. For the CRYSTMAS trial, “Frese-
nius Kabi was involved in the study design, analysis and 
preparation of the report” [21]. The FIRST trial “was sup-
ported by an unrestricted educational grant from Frese-
nius-Kabi who also provided the study fluids”; the lead 
author and two of the five co-authors “have received 
honoraria and travel support from Fresenius-Kabi” [20]. 
Boussekey et al. [19] declared that they have no compet-
ing interests.
It is concluded that reporting bias is a problem in vol-
ume resuscitation research not only because of effects of 
the retraction of studies by Bold et al. on results of meta-
analyses [14, 16] but also because of selective underre-
porting of adverse events in patients receiving “modern” 
HES [19–21].
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